Program Discovery Preclinical Phase 1 Phase 2 Phase 3
Hepatitis C CC-31244
(Pan-genotypic NS5B NNI)
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

CC-31244, a non-nucleoside polymerase inhibitor, is a potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. It has the potential to be an important component in an all-oral ultra-short HCV combination therapy.

In two Phase 1 studies, CC-31244 showed an acceptable safety profile in both healthy volunteers and HCV-infected patients. There were no serious adverse events or discontinuations due to adverse events. The mean HCV viral load reduction was 1,000-fold at 48 hours and a sustained post-treatment antiviral effect after seven days of treatment.

We expect to commence a Phase 2a study in the first quarter of 2018 and report topline results before year end.